ArticleGynecologic oncology2018
The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: A prospective case control study.
Article in Gynecologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of endometrial cancer risk with hypertension- an updated meta-analysis of observational studies.Scientific reports · 2024Pooled it
- PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Trial
- Cancer of the corpus uteri: A 2025 update.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Review
- Critical Care Management of Surgically Treated Gynecological Cancer Patients: Current Concepts and Future Directions.Cancers · 2025Review
- 'It's not a solution to keep telling me to lose weight!' Exploring endometrial cancer survivors' experiences of nutrition and well-being advice: A qualitative study.The Australian & New Zealand journal of obstetrics & gynaecology · 2025Article
- Enhanced efficacy and safety of combining Aidi injection with megestrol acetate for endometrial cancer treatment.American journal of translational research · 2025Article
- Contextualizing racial associations in gene expression in patients with uterine serous carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Genetic association of lipids and lipid-lowering drug target genes with Endometrial carcinoma: a drug target Mendelian randomization study.Frontiers in endocrinology · 2024Article
- The interplay of obesity, microbiome dynamics, and innovative anti-obesity strategies in the context of endometrial cancer progression and therapeutic approaches.Biochimica et biophysica acta. Reviews on cancer · 2023Review
- Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer.Heart (British Cardiac Society) · 2023Article
- Associations of novel serum lipid index with epithelial ovarian cancer chemoresistance and prognosis.Frontiers in oncology · 2023Article
- Analysis of Baseline Serum Lipid Profile for Predicting Clinical Outcomes of Patients with Extensive-Stage Small Cell Lung Cancer.Cancer management and research · 2023Article
- Prospective Cohort Study of Pre- and Postdiagnosis Obesity and Endometrial Cancer Survival.Journal of the National Cancer Institute · 2022Article
- Assessing Metabolic Risk Factors for LVSI in Endometrial Cancer: A Cross-Sectional Study.Therapeutics and clinical risk management · 2022Article
- Weight Loss During Intrauterine Progestin Treatment for Obesity-associated Atypical Hyperplasia and Early-Stage Cancer of The Endometrium.Cancer prevention research (Philadelphia, Pa.) · 2021Article
- Article
- Article
- BF175 inhibits endometrial carcinoma through SREBP-regulated metabolic pathways in vitro.Molecular and cellular endocrinology · 2021Article
- Percutaneous Coronary Intervention in Patients With Gynecological Cancer: Machine Learning-Augmented Propensity Score Mortality and Cost Analysis for 383,760 Patients.Frontiers in cardiovascular medicine · 2021Article
- Application of Jianpi Xiaoai Recipe Combined with Cisplatin and Adriamycin in the Treatment of Endometrial Cancer and Its Effect on Disease Control Rate.Evidence-based complementary and alternative medicine : eCAM · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCardiovascular disease is a major cause of death in endometrial cancer survivors. The aim of this study was to determine whether women newly diagnosed with endometrial cancer have a higher prevalence of cardiovascular risk factors than the general population.
methodsThe prevalence of adequately treated and unrecognized/inadequately treated cardiovascular risk factors and the corresponding 10-year cardiovascular risk by QRISK2 score was measured in 150 consecutive women undergoing primary treatment for endometrioid endometrial cancer in the North West of England, and 746 age and ethnicity-matched control women from the Health Survey for England 2014.
resultsWomen with endometrial cancer had higher proportions of obesity (BMI≥30 60.7% vs. 32.4%, p<0.0001) and a preponderance of unrecognized and inadequately treated cardiovascular risk factors. Compared with controls, endometrial cancer cases had a higher prevalence of incident hyperglycemia (57.2%vs.11.5%, p<0.0001), total: HDL cholesterol ratio>4.5 (26.7%vs.13.7%, p<0.0001), and were more likely to have three or more cardiovascular risk factors (22%vs.6%, p<0.0001). This equates to a higher 10-year cardiovascular risk (median QRISK2 score 12.6% vs. 8.8%, p<0.0001). Optimization of risk factors would have a greater impact on absolute cardiovascular disease risk for cases than controls (QRISK2 score reduction 1.8% vs. 0.7%).
conclusionsWomen undergoing primary treatment for endometrial cancer have a higher prevalence of cardiovascular risk factors than women without the disease. Early identification and treatment of these risk factors could improve outcomes for endometrial cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.